Akili
The publicly traded company, which announced it was seeking strategic alternatives for its business last month, will go private thanks to the merger.
Carebook reports record revenue and the first quarter of positive adjusted EBITDA, while Cue Health sees large net and adjusted EBITDA losses.
The company also announced its intentions to seek FDA approval for EndeavorOTC, its over-the-counter product for adults with ADHD.
Video game-based therapeutic company Akili and baby tech company Owlet also post first quarter results.
Boehringer Ingelheim and Click Therapeutics initiate clinical trial on PDTx treatment for schizophrenia and Akili's EndeavorRx shows promise for adults with ADHD.
Earlier this year, the prescription digital therapeutics company said it would put programs related to cognitive health outside of ADHD on hold.
The prescription digital therapeutics company will also put non-ADHD products in development on hold to "conserve capital and focus."
Akili, Oscar Health and Bright Health also post third quarter results.
Matt Franklin, Akili Interactive's president and COO, explains the company's strategy for launching EndeavorRx, its video game digital therapeutic for children with ADHD.
The newly public company, now trading on Nasdaq under the ticker symbol "AKLI," will use the proceeds from the transaction to launch EndeavorRx, its video game-like digital therapeutic for children with ADHD.